Short Interest in Elekta AB (OTCMKTS:EKTAY) Declines By 62.4%

Elekta AB (OTCMKTS:EKTAY – Get Free Report) was the recipient of a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 6,134 shares, a drop of 62.4% from the July 30th total of 16,311 shares. Based on an average trading volume of 5,460 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.0% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Elekta currently has a consensus rating of “Reduce”.

Get Elekta alerts:

Check Out Our Latest Stock Analysis on EKTAY

Elekta Stock Up 2.4%

Shares of OTCMKTS EKTAY traded up $0.13 during mid-day trading on Friday, reaching $5.63. The company had a trading volume of 686 shares, compared to its average volume of 3,758. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.68 and a current ratio of 0.87. Elekta has a twelve month low of $4.35 and a twelve month high of $6.93. The stock’s 50 day moving average is $5.20 and its 200-day moving average is $5.70. The stock has a market capitalization of $2.08 billion, a PE ratio of -46.91 and a beta of 1.01.

Elekta (OTCMKTS:EKTAY – Get Free Report) last issued its earnings results on Thursday, August 27th. The company reported $0.07 EPS for the quarter. Elekta had a positive return on equity of 13.31% and a negative net margin of 2.38%.The firm had revenue of $372.30 million for the quarter. As a group, equities analysts anticipate that Elekta will post 0.43 earnings per share for the current fiscal year.

About Elekta

(Get Free Report)

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

Further Reading

• Five stocks we like better than Elekta
• From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
• These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
• Venture Into High-Volatility Corners of the Market With These 3 ETFs
• 3 Retail Stocks to Watch After a Big Consumer Earnings Week

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.